DAE HWA Pharmaceutical Co., Ltd.
Financials
Valuation Metrics
DAE HWA Pharmaceutical Co., Ltd.'s Market Cap is ₩1726B. At end of 2025 it was ₩3245B. Ranked #903 of 2,436 in KR market (top 37%), #425 of 1,649 on KOSDAQ (top 26%), #100 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 43%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 172.58B KRW | KR#903/2,436 Sec#100/234 |
| Revenue | 143.42B KRW | KR#1,184/2,436 Sec#73/234 |
| Net Income | 2.36B KRW | KR#1,327/2,436 Sec#93/234 |
| Total Assets | 222.33B KRW | KR#1,215/2,436 Sec#89/234 |
| Net Assets | 85.06B KRW | KR#1,510/2,436 Sec#125/234 |
| Employees | 365 | KR#661/2,436 Sec#58/234 |
| Value | ||
| P/E | 73.08x | KR#1,404/2,436 Sec#93/234 |
| P/B | 2.03x | KR#1,948/2,436 Sec#143/234 |
| PEG | 1.49x | KR#782/2,436 Sec#50/234 |
| P/S | 1.20x | KR#1,517/2,436 Sec#88/234 |
| EV/EBITDA | 107.79x | KR#1,476/2,436 Sec#102/234 |
| FCF Yield | 3.12% | KR#992/2,436 Sec#65/234 |
| Profitability | ||
| ROE | 2.78% | KR#1,252/2,436 Sec#89/234 |
| ROA | 1.06% | KR#1,305/2,436 Sec#93/234 |
| Op. Margin | 1.73% | KR#1,389/2,436 Sec#101/234 |
| Revenue Growth | 0.99% | KR#1,378/2,436 Sec#130/234 |
| Earnings Growth | 48.91% | KR#575/2,436 Sec#33/234 |
| Financial Health | ||
| Debt Ratio | 261.39% | KR#2,031/2,436 Sec#213/234 |
| Total Debt | 101.00B KRW | KR#711/2,436 Sec#43/234 |
| FCF | 5.38B KRW | KR#882/2,436 Sec#61/234 |
| Cash | 5.49B KRW | KR#1,952/2,436 Sec#172/234 |
| Current Ratio | 0.53x | KR#2,235/2,436 Sec#211/234 |
| Net Debt/EBITDA | 38.40x | KR#1,513/2,436 Sec#109/234 |
| Dividend | ||
| Div. Yield | 1.70% | KR#979/2,436 Sec#52/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -38.93% | KR#1,812/2,436 Sec#161/234 |
| 1M Return | 0.22% | KR#861/2,436 Sec#75/234 |
| From 52W High | -62.77% | KR#1,848/2,436 Sec#155/234 |
| 1Y MDD | -66.22% | KR#1,756/2,436 Sec#147/234 |
| Trading | ||
| Volume | 45,450 shares | KR#1,389/2,436 Sec#138/234 |
| Foreign Own. | 0.46% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 98 KRW | KR#1,359/2,436 Sec#95/234 |
| BPS | 4,388 KRW | KR#1,549/2,436 Sec#115/234 |
Company Info
Established in 1984 and listed on KOSDAQ in 2003, Daehwa Pharmaceutical is an innovative pharmaceutical company with 5 subsidiaries, including 3 domestic and 2 overseas. It engages in pharmaceutical manufacturing, wholesale, medical information systems, and the manufacturing and sales of pharmaceutical raw materials, cosmetics, and medical devices. The company produces treatments for infectious and digestive diseases at its GMP-certified factories, capturing 65% of the domestic OEM market. Daehwa Pharmaceutical is headquartered in Hoengseong-gun, Gangwon-do.